Key Highlights
- IceCure Medical (NASDAQ:ICCM) indicated at USD 0.9200 pre-market on Tuesday, November 10, 2026, up 11.87% from a calculated prior close of USD 0.8224 set on Monday, November 9.
- Published market data shows a market Capitalization of USD 2.82 million on 3.43 million shares, with a 52-week range of USD 0.65 to USD 22.50.
- Liquidity is thin: 14,994 shares changed hands on the quote page against an average Volume of 154.15 thousand, or about 9.7% of a normal day, calculated.
- Revenue was USD 3,379,000 for fiscal 2025 and USD 3.95 million over the trailing twelve months, but no catalyst was identified in published coverage for November 10.
What Moved IceCure Medical Pre-Market (+11.87%)
The indication of USD 0.9200 on Tuesday, November 10, 2026 is a gain of USD 0.0976 per share, calculated from the 11.87% screener change and a prior close of USD 0.8224. The published quote page rounds that close to USD 0.82. The price sits 95.9% below the 52-week high of USD 22.50 and 41.5% above the low of USD 0.65, both calculated. Multiplying the indicated price by 3.43 million shares gives about USD 3.16 million, calculated, against the USD 2.82 million market capitalization on the quote page. Two searches found no company release or filing dated November 9 or 10, 2026, so no catalyst is identified in published coverage. Revenue of USD 3.95 million over twelve months puts the stock at roughly 0.8 times trailing sales, calculated.
The Rationale: No Catalyst Identified, and What Usually Drives Such Moves
IceCure sells the ProSense cryoablation system, which freezes tumors, and earlier published coverage tied a one-day surge of 203% to a 70% increase in US ProSense adoption. That report is background, not an explanation for November 10. General context: medical device small caps often jump on regulatory news, reimbursement updates, installation counts or conference presentations, and they also move on retail momentum when a stock sits near a low. A price below USD 1.00 can attract a Nasdaq minimum bid notice, and a reverse split is a common response. The 52-week high of USD 22.50 is far above the price, which suggests a large share count change occurred in the past, so historic charts may be adjusted.
Valuation, Liquidity, 52-Week Range and Risks
At USD 2.82 million, the market capitalization is below one year of revenue of USD 3.95 million, yet the company is loss-making and depends on outside capital. The trading figures are small: 14,994 shares versus a 154.15 thousand average, so a few trades can move the price and spreads can be wide. Pre-market quotes in a stock with 3.43 million shares can swing by double digits on very little money. The main risks are dilution from new offerings, a bid-price deficiency, regulatory timing and Reversal at the 9:30 a.m. ET open. Nothing in the data implies the move will continue.
Where Things Stand
IceCure Medical (NASDAQ:ICCM) is indicated 11.87% higher pre-market at USD 0.9200 with no identified catalyst. The prior close was USD 0.82, market capitalization is USD 2.82 million, and the 52-week range is USD 0.65 to USD 22.50. Volume of 14,994 shares versus 154.15 thousand on average shows the quote is thin. Investors should check the next company release, any capital raise and any Nasdaq notice before reading anything into the move, since a move of this size on 14,994 shares says little about demand.






Please wait processing your request...